Catherine Louise Heurteaux

This inventor holds 6 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Moleac Pte Ltd., Université De Nice Sophia Antipolis. Active years: 2001-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Catherine Louise Heurteaux. Retrieved from https://idiyas.com/inventor/catherine-louise-heurteaux

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 6)

% Patents Active = 83.3

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 6(Granted Patents)

Location History:

Antibes, FR (2001 - 2019)
La Colle sur Loup, FR (2019 - 2022)

Company Filing History:

4 out of 5,383

Centre National De La Recherche Scientifique

Université De Nice Sophia Antipolis

where one patent can have more than one assignee

Years Active: 2001-2022

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11220527 - Peptides derived from the propeptide NTSR3 and their use in the treatment of depression (2022-01-11),

2. 10251937 - Retro-inverso analogs of spadin display increased antidepressant effects (2019-04-09),

3. 10188688 - Therapy for promoting cell growth (2019-01-29),

4. 9289459 - Therapy for promoting cell growth (2016-03-22),

5. 8252748 - Peptide derived from neurotensin receptor 3 and use thereof in the treatment of psychiatric diseases (2012-08-28),

6. 6239156 - Method for the prevention of ischemic spinal cord injury caused by aortic crossclamping (2001-05-29),

Title: The Innovative Contributions of Catherine Louise Heurteaux

Introduction

Catherine Louise Heurteaux is a prominent inventor based in Antibes, France. She has made significant contributions to the field of biomedical research, particularly in the development of novel treatments for depression. With a total of six patents to her name, her work has garnered attention for its potential impact on mental health therapies.

Latest Patents

Catherine's latest patents include groundbreaking research on peptides derived from the propeptide NTSR3. These peptides are disclosed for their use in treating various diseases, especially depression. Another notable patent involves retro-inverso analogs of spadin, which display increased antidepressant effects. This patent describes compositions and pharmaceutical formulations containing these analogs, as well as methods for treating depression and blocking TREK-1 channel activity.

Career Highlights

Throughout her career, Catherine has worked with esteemed organizations such as the Centre National de la Recherche Scientifique and Moleac Pte Ltd. Her research has focused on innovative approaches to mental health treatment, showcasing her dedication to improving patient outcomes.

Collaborations

Catherine has collaborated with notable colleagues, including Jean Mazella and Marc Borsotto. These partnerships have contributed to her success in advancing research and developing effective therapeutic solutions.

Conclusion

Catherine Louise Heurteaux's contributions to the field of biomedical research, particularly in the treatment of depression, highlight her innovative spirit and commitment to improving mental health therapies. Her patents and collaborations reflect her significant impact on the scientific community.

Profile summary based on public USPTO records.